Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8871 100 µg · 1 trial · 1 indication
The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in trough FEV1 on Day 15
| Arm | Type | Description |
|---|---|---|
| AZD8871 100 µg | EXPERIMENTAL | The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products. |
| Placebo | PLACEBO_COMPARATOR | The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period. |
| AZD8871 600 µg | EXPERIMENTAL | The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products. |
| Name | Type | Description |
|---|---|---|
| AZD8871 100 µg | DRUG | The subjects will receive one dose of AZD8871 100 µg single dose DPI. |
| AZD8871 600 µg | DRUG | The subjects will receive AZD8871, 600 µg single dose DPI. |
| Placebo | DRUG | The subject will receive Placebo single dose DPI. |
Inclusion Criteria: 1. Patient who provided of informed consent prior to any study-specific procedures 2. Male or female 40 to 80 years of age (both inclusive) at Screening (Visit 1). A female is eligible to enter and participate in the study if she is of non-childbearing potential. Note: A fem...
AZD8871 100 µg is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is administered via inhalation. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AZD8871 100 µg is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the drug's efficacy, pharmacokinetics, safety, and tolerability in patients with COPD.
AZD8871 100 µg is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. A Phase 2 trial has been completed to assess its effects in patients with Chronic Obstructive Pulmonary Disease (COPD).
AZD8871 100 µg has been studied in one completed Phase 2 clinical trial with the identifier NCT02971293. This randomized, double-blind, placebo-controlled study enrolled 42 participants with Chronic Obstructive Pulmonary Disease (COPD) and was conducted in Germany and the United Kingdom.
AZD8871 100 µg is a specific dosage strength of the drug AZD8871. The 100 µg designation refers to the amount of the active ingredient in each inhaled dose. The drug is being developed by AstraZeneca for the treatment of Chronic Obstructive Pulmonary Disease (COPD).